Effects of insulin dependence on inflammatory process, thrombotic mechanisms and endothelial function, in patients with type 2 diabetes mellitus and coronary atherosclerosis

Clinical Cardiology

Volumn 30, Issue 6, 2007, Pages 295-300

  Antoniades, Charalambos ^a   Tousoulis, Dimitris ^a   Marinou, Kyriakoula ^a   Papageorgiou, Nikos ^a   Bosinakou, Erini ^a   Tsioufis, Costas ^a   Stefanadi, Elli ^a   Latsios, George ^a   Tentolouris, Costas ^a   Siasos, Gerasimos ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Coronary artery disease; Diabetes mellitus; Endothelium; Inflammation

Indexed keywords

ACETYLSALICYLIC ACID; AUTACOID; BIGUANIDE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN C; SULFONYLUREA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; CORRELATION ANALYSIS; DIET RESTRICTION; DRUG USE; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; GREECE; HUMAN; INFLAMMATION; INSULIN DEPENDENCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PLETHYSMOGRAPHY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; THROMBOSIS;

AGED; BIGUANIDES; BLOOD COAGULATION FACTORS; CORONARY ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FEMALE; FOREARM; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN; INTERLEUKIN-6; MALE; MIDDLE AGED; PROTEIN C; REGIONAL BLOOD FLOW; REGISTRIES; SULFONYLUREA COMPOUNDS; THROMBOSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1; VASODILATION;

EID: 34250811431     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20101     Document Type: Article

References (27)

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without Prior Myocardial Infarction. N Engl J Med 1998;339:229-234
2. Pfutzner A, Marx N, Lubben G, Langenfeld M, Walcher D, et al.: Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005;45:1925-1931
3. Wellen KE, Hotamisligil GS: Inflammation, stress, and diabetes. J Clin Invest 2005;115:1111-1119
4. Morishita E, Asakura H, Jokaji H, Saito M, Uotani C, et al.: Hypercoagulability and high lipoprotein(a) levels in patients with type II diabetes mellitus. Atherosclerosis 1996;120:7-14
5. Sjoholm A, Nystrom T: Endothelial inflammation in insulin resistance. Lancet 2005;365:610-612
6. Hotamisligil GS: Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 2003;27(suppl 3):S53-S55
7. Muis MJ, Bots ML, Grobbee DE, Stolk RP: Insulin treatment and cardiovascular disease; friend or foe? A point of view. Diabet Med 2005;22:118-126
8. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P: Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994;94:2511-2515
9. Laakso M, Edelman SV, Brechtel G, Baron AD: Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest 1990;85:1844-1852
10. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-1057
11. Tousoulis D, Antoniades C, Stefanadis C: Evaluating endothelial function in humans: a guide to invasive and non-invasive techniques. Heart 2005;91:553-558
12. Pyorala M, Miettinen H, Laakso M, Pyorala K: Plasma insulin and all-cause, cardiovascular, and noncardiovascular mortality: the 22-year follow-up results of the Helsinki Policemen Study. Diabetes Care 2000;23:1097-1102
13. Unwin N, Shaw J, Zimmet P, Alberti KG: Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002;19:708-723
14. Dandona P, Aljada A, Mohanty P: The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm. Diabetologia 2002;45:924-930
15. Aljada A, Ghanim H, Saadeh R, Dandona P: Insulin inhibits NFkappaB and MCP-1 expression in human aortic endothelial cells. J Clin Endocrinol Metab 2001;86:450-453
16. Aljada A, Saadeh R, Assian E, Ghanim H, Dandona P: Insulin inhibits the expression of intercellular adhesion molecule-1 by human aortic endothelial cells through stimulation of nitric oxide. J Clin Endocrinol Metab 2000;85:2572-2575
17. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, et al.: Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 2001;86:3257-3265
18. Harte A, McTernan P, Chetty R, Coppack S, Katz J, et al.: Insulin-mediated Upregulation of the renin angiotensin system in Human Subcutaneous Adipocytes is reduced by Rosiglitazone. Circulation 2005;111:1954-1961
19. Golovchenko I, Goalstone ML, Watson P, Brownlee M, Draznin B: Hyperinsulinemia enhances transcriptional activity of nuclear factor-kappaB induced by angiotensin II, hyperglycemia, and advanced glycosylation end products in vascular smooth muscle cells. Circ Res 2000;87:746-752
20. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, et al.: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995;26:57-65
21. Diaz R, Paolasso EA, Piegas LS, Tajer CD, Moreno MG, et al.: Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Circulation 1998;98:2227-2234
22. Calles-Escandon J, Cipolla M: Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001;22:36-52
23. Goalstone ML, Natarajan R, Standley PR, Walsh MF, Leitner JW, et al.: Insulin potentiates platelet-derived growth factor action in vascular smooth muscle cells. Endocrinology 1998;139:4067-4072
24. Vischer UM, Emeis JJ, Bilo HJ, Stehouwer CD, Thomsen C, et al.: von Willebrand factor (vWf) as a plasma marker of endothelial activation in diabetes: improved reliability with parallel determination of the vWf propeptide (vWf:AgII). Thromb Haemost 1998;80:1002-1007
25. Carr ME: Diabetes mellitus: a hypercoagulable state. J Diabetes Complicat 2001;15:44-54
26. Yamamoto K, Shimokawa T, Kojima T, Loskutoff DJ, Saito H: Regulation of murine protein C gene expression in vivo: effects of tumor necrosis factor-alpha, interleukin-1, and transforming growth factor-beta. Thromb Haemost 1999;82:1297-1301
27. Vukovich TC, Schernthaner G: Decreased protein C levels in patients with insulin-dependent type I diabetes mellitus. Diabetes 1986;35:617-619